Similarities and differences between the adjuvant oxaliplatin-based trials MOSAIC and NSABP C-07

Authors: Boni, C., André, T., Banzi, M.C., Hickish, T., Tabernero, J., Clingan, P., Chibaudel, B. and De Gramont, A.

Journal: Current Colorectal Cancer Reports

Volume: 5

Issue: 3

Pages: 166-170

eISSN: 1556-3804

ISSN: 1556-3790

DOI: 10.1007/s11888-009-0024-7

Abstract:

Based on the results of the MOSAIC trial that were recently confirmed by the NSABP protocol C-07 study, the combination of oxaliplatin and 5-fluorouracil has become the standard adjuvant treatment for patients with stage III colon cancer. These pivotal studies confirm a similar, significant advantage in populations with stage II and III disease; however, they show a remarkable difference in toxicity, with greater risk of life-threatening complications (eg, diarrhea and bowel wall injury) in the NSABP C-07 trial. In this article, we analyze the differences and similarities between these studies. Copyright © 2009 by Current Medicine Group LLC.

Source: Scopus

Similarities and differences between the adjuvant oxaliplatin-based trials, MOSAIC and NSABP C-07

Authors: Boni, C., Andre, T., Banzi, M.C., Hickish, T.F., Tabernero, J., Clingan, P., Chibaudel, B. and De Gramont, A.

Journal: Current Colorectal Cancer Reports

Volume: 5

Pages: 166-170

ISSN: 1556-3790

DOI: 10.1007/s11888-009-0024-7

Abstract:

Based on the results of the MOSAIC trial that were recently confi rmed by the NSABP protocol C-07 study, the combination of oxaliplatin and 5-fl uorouracil has become the standard adjuvant treatment for patients with stage III colon cancer. These pivotal studies confi rm a similar, signifi cant advantage in populations with stage II and III disease; however, they show a remarkable difference in toxicity, with greater risk of life-threatening complications (eg, diarrhea and bowel wall injury) in the NSABP C-07 trial. In this article, we analyze the differences and similarities between these studies.

Source: Manual

Preferred by: Tamas Hickish